Bevacizumab biosimilar - Shanghai Henlius BiotechAlternative Names: HLX 04; rhuMAb-VEGF biosimilar - Shanghai Henlius Biotech
Latest Information Update: 27 Feb 2017
At a glance
- Originator Shanghai Henlius Biotech
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Colorectal cancer
Most Recent Events
- 27 Feb 2017 Shanghai Henlius Biotech plans a phase I trial for Colorectal cancer in China (ChiCTR-IIR17010718)